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Disturbances in mitochondrial biogenesis and bioenergetics, combined with
neuroinflammation, play cardinal roles in the cognitive impairment during aging
that is further exacerbated by transient cerebral ischemia. Both near-infrared (NIR)
photobiomodulation (PBM) and Coenzyme Q10 (CoQ10) administration are known to
stimulate mitochondrial electron transport that potentially may reverse the effects of
cerebral ischemia in aged animals. We tested the hypothesis that the effects of PBM and
CoQ10, separately or in combination, improve cognition in a mouse model of transient
cerebral ischemia superimposed on a model of aging. We modeled aging by 6-week
administration of D-galactose (500 mg/kg subcutaneous) to mice. We subsequently
induced transient cerebral ischemia by bilateral occlusion of the common carotid
artery (BCCAO). We treated the mice with PBM (810 nm transcranial laser) or CoQ10
(500 mg/kg by gavage), or both, for 2 weeks after surgery. We assessed cognitive
function by the Barnes and Lashley III mazes and the What-Where-Which (WWWhich)
task. PBM or CoQ10, and both, improved spatial and episodic memory in the mice.
Separately and together, the treatments lowered reactive oxygen species and raised ATP
and general mitochondrial activity as well as biomarkers of mitochondrial biogenesis,
including SIRT1, PGC-1α, NRF1, and TFAM. Neuroinflammatory responsiveness
declined, as indicated by decreased iNOS, TNF-α, and IL-1β levels with the PBM
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and CoQ10 treatments. Collectively, the findings of this preclinical study imply that the
procognitive effects of NIR PBM and CoQ10 treatments, separately or in combination,
are beneficial in a model of transient global brain ischemia superimposed on a model of
aging in mice.
Keywords: transcranial photobiomodulation, Coenzyme Q10, aging, global ischemia, mitochondrial biogenesis,
neuroinflammation, learning and memory
INTRODUCTION
Aging is a multifactorial process characterized by progressive
decline of physiological functions and potential development of
a wide array of diseases (López-Otín et al., 2013). Cognitive
impairment is one of the most important aspects of aging brains
(Harada et al., 2013). Mitochondrial dysfunction negatively
affects neuronal metabolism by means of oxidative stress.
Neuroinflammation is active in normally aging brains and
is implicated in subsequent cognitive decline (Bishop et al.,
2010; Khorrami et al., 2014). As a consequence of the limited
availability of aged animals, and the costs of obtaining and
housing an adequate number of such animals for experimental
studies, natural aging models can be prohibitive. As sufficient
natural aging is lengthy, rapid access to aged animals is a limiting
factor of pre-clinical research. As an alternative approach, we
modeled natural aging by chronic administration of D-galactose
to rodents. D-galactose is a reducing hexose sugar that enters
the brain and reacts with many cellular components at high
concentration, producing oxidative damage to lipids and DNA
(Ho et al., 2003; Sadigh-Eteghad et al., 2017). The chronic
D-galactose treatment induces changes that resemble natural
aging and mimics several characteristics of brain aging (Wei
et al., 2005; Sadigh-Eteghad et al., 2017). The administration to
rodents has been shown to cause neurocognitive impairments,
including memory deficits, increased inflammatory responses
and mitochondrial dysfunction (Shan et al., 2009; Sadigh-
Eteghad et al., 2017; Salehpour et al., 2017).
Cerebral ischemia is a major risk factor during aging with
consequences for the occurrence and severity of cognitive
impairment (Chen et al., 2010). Cardiovascular events such
as heart attacks and strokes are more common in older
individuals, and the likelihood and severity of brain damage
are correspondingly higher due to mitochondrial dysfunction.
Therefore, age-related structural and functional changes
potentially increase the vulnerability of the brain to ischemic
insults (Ueno et al., 2002). During cerebral ischemia, the
reduced blood flow and the subsequent lack of oxygen,
glucose, and other nutrients disturb cellular homeostasis
(Chen et al., 2011). Excessive production of reactive oxygen
species (ROS) in mitochondria activates signaling pathways
that ultimately result in further mitochondrial dysfunction
and abnormal bioenergetics (Onyango et al., 2010; Olmez
and Ozyurt, 2012). Transient bilateral common carotid
artery occlusion (BCCAO) is a well-established experimental
approach in rodents that exploits the adverse influence
of acute cerebral hypoperfusion on cognitive mechanisms
(Schiavon et al., 2014).
Due to the inverse relationship between the capacity
for endogenous mitochondrial biogenesis and chronological
aging, the ability of the brain to recover from an ischemic
insult is much reduced in older individuals (López-Lluch
et al., 2008). Upstream regulators of mitochondrial biogenesis,
e.g., transcription factors such as SIRT1 (silent mating-type
information regulation 2 homolog 1) and PGC1-α (peroxisome
proliferator-activated receptor gamma coactivator-1 alpha) play
key roles in the pathophysiology of brain ischemia (Chen
et al., 2011). Down-regulation of markers of mitochondrial
biogenesis such as NRF1 (nuclear respiratory factor 1) and
TFAM (mitochondrial transcription factor A), as well as lower
numbers of mitochondria, are observed in reperfusion injury
after ischemia (Liu et al., 2014). In addition, decreased cerebral
blood flow (CBF) yields pro-inflammatory responses such as
production of tumor necrosis factor-α (TNF-α) and interleukin
(IL) IL-1β from the ischemic endothelium which leads to
larger infarction volumes and exacerbates brain injury (Anrather
and Iadecola, 2016). In addition, NO produced by inducible
NO synthase (iNOS) in activated microglia and damaged
cerebrovascular endothelium is involved in the detrimental
inflammatory response to an ischemic insult (Zoppo et al., 2000).
The evidence suggests that mitochondria are the key targets both
of ischemic injury and brain aging (Gjedde, 2005; Reddy, 2008).
Here, we exploit the knowledge that the mitochondria are targets
both of aging and of ischemic insults to the brain, with a potential
for development of novel therapeutic approaches based on
stimulation of mitochondrial biogenesis and bioenergetics. In this
study, the interventions stimulated mitochondrial biogenesis and
bioenergetics by regulation of the electron transfer chain (ETC).
The first intervention of interest is an application of a low
power of light. Transcranial photobiomodulation (PBM) with
low-levels of red to near-infrared (NIR) light (wavelengths
600–1100 nm) has been proposed as a non-invasive method
of stimulation in brain disorders (Hamblin, 2016; Salehpour
and Rasta, 2017). The procognitive benefits of this light-based
intervention have been observed in animal models of Alzheimer’s
disease (De Taboada et al., 2011) and aging (Salehpour et al.,
2017), and in patients with acute stroke (Hamblin, 2017),
traumatic brain injury (TBI) (Naeser et al., 2014; Morries et al.,
2015), and dementia (Berman et al., 2017; Saltmarche et al.,
2017). Absorption of light by mitochondrial complex IV, the
cytochrome c oxidase (CCO) and subsequent increase in ATP
production have been proposed as a main mechanism of action
of PBM therapy (de Freitas and Hamblin, 2016), thought to act
by augmentation of cerebral bioenergetics (Dong et al., 2015),
inhibition of neuroinflammation (Lee et al., 2016; Salehpour et al.,
2018b), and increase of antioxidant activity (Lu et al., 2017).
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The second potential intervention of interest is administration
of Coenzyme Q10 (CoQ10), also known as ubiquinone, that
transfers electrons from complexes I and II to complex III
(Dallner and Sindelar, 2000). CoQ10 supplementation is held
to improve mitochondrial function by promotion of ATP
production (Hargreaves, 2014) and mitochondrial biogenesis
(Noh et al., 2013; Khorrami et al., 2014). In neurons, the action
of CoQ10 has been shown to protect mitochondria and lipid
membranes (Somayajulu et al., 2005), as has the beneficial effect
of CoQ10 supplementation on the inflammatory response of
endothelial cells (Gao et al., 2012), and the neuroprotective
properties of CoQ10 against learning impairment in aged animals
(Mcdonald et al., 2005; Shetty et al., 2013).
Here, we test the hypothesis that the added effects of
senescence modeled by D-galactose in mice followed by BCCAO
can be reversed by the beneficial effects on mitochondria
of NIR light PBM and CoQ10 supplementation (alone or in
combination), as evidenced by the potential procognitive and
neuroprotective actions of the interventions.
MATERIALS AND METHODS
Animals and Experimental Groups
According to the research design, 90 adult male BALB/c mice,
8–10-weeks-old and weighing 20–25 g, were purchased from
Laboratory Animal Center of Tabriz University of Medical
Sciences (TUOMS) Tabriz, Iran. Mice were socially housed in
standard cages (five/cage), kept under controlled conditions at
the temperature of 24 ± 2◦C on a 12/12 h light and dark
cycle, and fed standard pellet food with tap water ad libitum.
The experiments were performed under an approved protocol
of TUOMS Ethics Committee (No: IR.TBZMED.REC.1396.576)
and were in accordance with NIH guidelines. After a week of
adaptation, mice were randomly divided into two groups: control
(n = 15) and the artificially aged (AA) (n = 75). The control group
received normal saline (NS) (0.9% NaCl, 0.2 ml/mice) and the AA
group received D-galactose (500 mg/kg/daily) (Sigma, St. Louis,
MO, United States) by subcutaneous (s.c.) injection once per day
for 6 weeks (Salehpour et al., 2017). At the end of the sixth week,
mice in the AA group were divided into two groups: AA either
separately (n = 15) or followed by transient global brain ischemia
(GBI) (n = 60). The AA mice received sham surgery. Ischemic
AA mice were then subdivided into four groups that received (I)
sham PBM+ vehicle gavage (AA+GBI), (II) sham PBM+CoQ10
gavage (CoQ10), (III) real PBM+ vehicle gavage (PBM), and (IV)
real PBM+ CoQ10 gavage (PBM+ CoQ10) (n = 15 per group).
We compared a vehicle-treated group of AA mice to a
vehicle-treated control group (AA vs. control), and we compared
a vehicle and sham-laser treated group of AA mice that we
further stressed with transient GBI to the vehicle-treated group
of AA mice (AA+GBI vs. AA). Three globally ischemic AA
groups then received three different therapeutic interventions
(CoQ10, PBM, or PBM+CoQ10) that we compared to a globally
brain ischemic group of AA mice (AA+GBI) given only sham
treatments (CoQ10, PBM, or PBM+CoQ10 vs. AA+GBI).
Figure 1 shows the study design including procedures
and time periods.
Surgery
We induced transient global cerebral ischemia with the BCCAO
method as previously described (Soares et al., 2016). Briefly,
animals were anesthetized with inhalation of isoflurane (4%) and
intraperitoneal injection of xylazine (4 mg/kg) and maintained
with 1.5% isoflurane in 70% nitrous oxide and 30% oxygen
through a plastic facemask. Rectal temperature was maintained
at 37◦C with a heating blanket and monitored during operation.
A midline anterior incision was made in the neck to expose the
both common carotid arteries. Each artery was encircled with
3-0 silk thread and the vagus nerve separated. Transient global
cerebral ischemia was induced by BCCAO for 20 min using
microaneurysm clips (Aesculap, Germany) and CBF reduction
was confirmed by laser Doppler flowmeter (LDF) (LaserFlo,
Vasamedics Inc., St Paul, MN, United States). Then, anesthesia
was turned off, the skin incision was sutured, and the mice were
placed in a recovery cage. For sham surgery, the AA group was
exposed to the same anesthetic and surgical procedures without
occlusion of the carotid arteries.
Treatments
We performed the PBM therapy with a NIR laser (Thor
Photomedicine, Chesham, United Kingdom) at 810 nm
wavelength, 200 mW maximum output power, and 6.66 W/cm2
irradiance with a spot size of 0.03 cm2. The laser operated at
FIGURE 1 | Timescale of D-galactose administration, global ischemia induction, PBM and/or CoQ10 treatments, behavioral tasks, and sampling.
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10-Hz PW frequency on at 88% duty cycle. For each irradiation
session a total energy of 1 J (fluence of 33.3 J/cm2) was delivered
to the head (Salehpour et al., 2017). For transcranial PBM
therapy, each mouse was held firmly and the laser probe was
positioned over the midline of the dorsal surface of the head
in region between eyes and ears. The CoQ10 was purchased
from Sigma-Aldrich (United States). The CoQ10 group received
the treatment (500 mg/kg/day) via gavage (Schilling et al.,
2001). CoQ10 was dissolved in soybean oil as a vehicle. The
combination group received the same daily dose of CoQ10 and
treated with PBM 2 hr before the gavage.
The AA+GBI group received oral vehicle and underwent
identical PBM therapy procedures except that the laser device
remained inactive. All oral administrations had a volume of
8 ml/kg body weight. All treatments were applied once a day for
14 consecutive days.
Behavioral Assessments
Neurological Impairment
In order to evaluate neurological performance, mice were
subjected to neurological severity score testing (NSS) on the day
before starting the learning and memory tasks. The motor ability,
balance, reflexes, and alertness of the animals were assessed as
different aspects of neurological outcome (Beni-Adani et al.,
2001). The scale ranges from 0 to 10. The intact control mice were
given the score of zero (0), whereas a score of 10 reveals greatest
neurological impairment. All behavioral testing was carried out
by one person blinded to the experimental groups.
Barnes Maze Task
The spatial learning and memory abilities were evaluated using
a Barnes task as described previously (Salehpour et al., 2017).
The maze consisted of a black circular platform 100 cm in
diameter with 20 evenly spaced holes located 3.0 cm from the
perimeter. A movable rectangular escape box (20 × 15 × 5 cm)
was located under the escape hole. The maze was placed in
a quiet room where spatial cues (four basic shapes: triangle,
square, circle, and horizontal rectangle) were located on the
walls. Mice were encouraged to escape by a buzzer (80 dB
white noise). The task procedure had three sessions including
adaptation, training, and a probe trial, and took 5 days. On
first day, each mouse was habituated to the task platform
by gently guiding the mouse from the maze center to the
target hole. The mouse was allowed to remain undisturbed in
the escape box for 1 min after entering it. Each mouse then
underwent 4 days of training with four 3-min trials per day,
each separated by a 3-min interval. 24 h following the last
training trial, a probe trial was performed, that is, the escape
box was removed and the mouse was allowed to explore the
maze freely for 3 min. Between trials, the maze was cleaned with
70% alcohol to remove odor cues. Trials were recorded using a
digital camera mounted above the maze and the performance
of mice was analyzed using a video tracking program Etho
VisionTM (Noldus, Netherlands). The performance during the
training trials was evaluated by the latency time to find the target
hole. Additionally, the time spent in the target quadrant, and
correct/wrong relative time (time spent around the holes) during
the probe session was calculated.
Lashley III Maze
Spatial reference memory and learning were evaluated using the
Lashley III maze task, which is based on navigation with visual
and food cues (Matzel et al., 2003). Briefly, the lateral walls and
ceiling of the maze were constructed from black or transparent
Plexiglas, respectively. The maze consisted of three separable
parts including start box, maze arms, and goal box. The maze
arms had four lanes that were evenly spaced along the maze. The
small cup containing sugar reward was located in the goal box
as motivation. Before the start of the test, mice were fasted for
12 h. Mice were moved to the testing room for 30 min prior to
placement in the maze. At the beginning of testing, each mouse
was placed in the start box for 15 s and then the Plexiglas sliding
door was opened to allow the animal to explore the four alleys of
the maze for 6 min. The trial is completed when the animal has
entered the goal box at the end of the maze. Mice were trained
once a day for 5 days and all experimental procedures were
recorded using a digital camera and analyzed by a video tracking
program Etho VisionTM (Noldus, Netherlands). The learning
index was measured as mean time in correct arms divided by total
escape time during 5 days. The number of errors (i.e., a turn in an
incorrect direction) and latency time to reach the goal box were
also parameters of interest (Bressler et al., 2010).
What-Where-Which (WWWhich) Task
This task has been described in detail earlier (Salehpour et al.,
2017) and is therefore described here briefly. The apparatus
consisted of two different contexts, namely contexts 1 and 2,
made of Plexiglas. All objects for testing were assembled from
LEGO R© bricks. At the beginning of the task, each mouse was
habituated to each context for 5 min for 1 day. After 24 h, as
an exposure session, two different objects (A and B) were first
located in the context 1 and the mouse was given 3 min to explore
it. Then, the mouse was returned to the cage for 30 s and the
locations of the objects were switched (B and A) in the context
2. Next, the mouse was placed in the context 2 and was allowed
to explore it for 3 min. The test session was carried out after
a 5 min interval, when the mouse encountered two copies of
one of the objects (A or B) located in one of the two contexts
(1 or 2) for 3 min. Exposure and test sessions were performed
in 2 trials for 2 days with new objects for each day. The total
observation time (sum of time spent exploring both novel and
familiar objects) and locomotor activity were videotaped and
data extracted using a video tracking program Etho VisionTM
(Noldus, Netherlands). The episodic-like memory was defined
by the discrimination index (DI) as follows: DI = (N−F)/(N+F),
where N and F represent the exploration time on the novel and
familiar objects, respectively.
Biochemical Assessments
Sampling and Mitochondrial Isolation
Mice were sacrificed with an overdose of ketamine (100 mg/kg)
and xylazine (10 mg/kg), at 24 h after the last behavioral test.
The whole brain (excluding cerebellum) was quickly taken out
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from the skull and placed in ice-cold isolation buffer. Then, brain
tissues were cut into small pieces and homogenized in ice-cold
extraction buffer. The samples were centrifuged at 600× g in 4◦C
for 5 min. The supernatant liquid was transferred into a new tube
and centrifuged at 12,000 × g in 4◦C for 15 min. The pellet was
resuspended in storage buffer. Protein levels were determined by
Bradford method (Bradford, 1976).
Mitochondrial ROS Levels
For evaluation of the ROS level in brain mitochondria, the
fluorescent dye, dichlorohydro-fluorescein diacetate (DCFDA),
was used (Novalija et al., 2003). The mitochondria were incubated
with 2-µM DCFDA at 37◦C for 20 min. The fluorescence
intensity was determined (λex = 485 nm, λem = 530 nm) in a
fluorescence microplate reader. The ROS levels were represented
as fluorescence intensity and normalized to samples protein.
ATP Colorimetric Assay
All procedures were done according the colorimetric assay kit
(MAK190, Sigma, United States). Briefly, the homogenized brain
tissue was mixed with ATP assay buffer followed by development
buffer and the absorbance was measured at 570 nm. A standard
curve was used to obtain the ATP concentration and presented in
units of µmol per g tissue.
Mitochondrial Activity
Mitochondrial labeling was performed using MitoTracker Probes
(Cell signaling, United States). The MitoTracker Green (MTG)
was directly added into mitochondrial suspension (100–400 nM)
and incubated for 30 min. The fluorescence intensity was
determined (λex = 490 nm, λem = 516 nm) in a fluorescence
microplate reader. The mitochondrial activity was represented as
fluorescence intensity and normalized to sample protein content.
Western Blotting
Cytosolic and mitochondrial proteins of interest were analyzed
by Western blot method as described previously (Sadigh-
Eteghad et al., 2015). Briefly, proteins were separated
using 12.5% polyacrylamide gel and transferred onto
a poly-vinylidene-difluoride (PVDF) membrane (Roche,
United Kingdom). Membranes were incubated with anti-SIRT1
(sc-15404), PGC1-α (sc-5815), NRF1 (sc-101102), TFAM (sc-
166965), iNOS (sc-8310), TNF-α (ab6671), and IL-1β (sc-7884)
primary antibodies in 1:500 concentration. Finally, membranes
were placed in ECL prime Western blotting detection reagent
(Amersham, United Kingdom). Signals were visualized by
exposure to autoradiography film (Kodak, United States). Anti-
GAPDH (sc-32233) and cytochrome c (sc-13156) antibodies
were used for internal control of cytosolic and mitochondrial
proteins, respectively. The signal intensity of each band was
quantitated using ImageJ 1.62 software (National Institutes of
Health, United States).
Statistics
Descriptive data were expressed as mean ± S.E.M. Comparison
of different experimental groups was carried out by a one-way
ANOVA followed by the post hoc Tukey test. All analyses were
performed using Graph Pad Prism 6.01 (Graph Pad Software Inc.,
La Jolla, CA, United States). A p-value < 0.05 was considered
statistically significant.
RESULTS
We designed the experiments to answer two main questions: Did
the cerebral ischemia further exacerbate the effects of artificial
aging, and did one or more of three hypothetically beneficial
interventions reverse the effects of the aging exacerbated by
ischemia? The design of the interventions yielded the assessments
below, as applied to each group of mice.
Behavioral Assessments
Neurological Severity
No mice in any experimental group exhibited any behavioral
change, as determined by NSS test (data not shown).
Barnes Maze
Training session
The values of the animals’ velocity indices revealed no statistical
differences among experimental groups for all four days of the
training session. The one-way ANOVA followed by Tukey test
showed that AA mice delayed the finding of the escape box on
the 2nd (p < 0.05), 3rd (p < 0.01), and 4th (p < 0.05) day. There
were no significant difference between the effects of artificial
aging with or without subsequent ischemia in terms of latency
(p > 0.05). The interventions, CoQ10 and PBM, both separately
and together, significantly reduced the latency on the 3rd and 4th
days of training (separately p < 0.05, together 3rd day p < 0.01,
4th day p< 0.001; Figure 2A).
Probe session
As shown in Figure 2B, the AA mice spent a significantly shorter
time in the target quadrant (p < 0.01). No significant difference
was observed between the aged mice with or without added
ischemia in terms of time spent in the target quadrant (p> 0.05),
but the subsequent treatment with CoQ10 and PBM separately
or together caused treated mice to spend more time (p < 0.05,
p< 0.01, and p< 0.001, respectively).
The correct-to-wrong relative times significant differed
between the AA and control groups (p < 0.001). There
were no significant differences between the AA and AA+GBI
groups (p > 0.05), but the CoQ10 (p < 0.01), PBM
(p < 0.05), and combination (p < 0.01) treatments significantly
increased the correct-to-wrong relative times in the probe
session (Figures 2C,D), although the effects of the three
treatments did not differ.
Lashley III Maze
As shown in Figures 3A,D, the mean latency to reach the goal box
was significantly higher in the AA group compared to the control
group on the 1st and 2nd (for both, p < 0.001), 3rd, 4th, and
5th (for all, p < 0.05) days. There were no significant differences
between the AA and AA+GBI groups in terms of mean latency
(p > 0.05). The latency time on the 2nd, 3rd, 4th, and 5th days
of training were significantly decreased after CoQ10 (p < 0.01,
p < 0.01, p < 0.001, and p < 0.001) and PBM treatments
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FIGURE 2 | (A) Escape latencies in training sessions in different groups. Differences among groups were analyzed for each day. (B) Time spent in the target
quadrant and (C) relative error time in probe sessions in different groups. (D) Corresponding heat maps display the combined traces of the mice from experimental
groups during the probe session. Values represent the mean ± SEM, (n = 15). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared with the NS (control). #p < 0.05,
##p < 0.01, and ###p < 0.001 compared with the AA + GBI. AA, artificially aged; CoQ10, Coenzyme Q10; GBI, global brain ischemia; NS, normal saline; PBM,
photobiomodulation; Veh, Vehicle.
(p < 0.05, p < 0.05, p < 0.001, and p < 0.01), respectively. In
addition, the combination group showed a significant decrease in
the latency on the 2nd (p< 0.05), 3rd (p< 0.01), 4th (p< 0.001),
and 5th (p< 0.01) days.
The mean value of the number of errors was significantly
higher in the AA group on days 2–5 days (for all, p< 0.05). There
were no significant differences between the AA and AA+GBI
groups in terms of the number of errors (p > 0.05). The number
of errors on the 4th and 5th days of training, respectively, were
decreased in CoQ10 (p < 0.01, and p < 0.05) and PBM (for both,
p < 0.05) groups. In addition, the combination group showed
a significant decrease in the number of errors on the 2nd and
3rd (for both, p < 0.05), 4th (p < 0.001), and 5th (p < 0.01)
days (Figure 3B).
As shown in Figure 3C, the AA mice exhibited a lower
learning index compared to control mice (p < 0.01). No
significant difference was observed between the AA and AA+GBI
groups in terms of learning index (p > 0.05). On the other hand,
CoQ10 (p< 0.01), PBM (p< 0.05), and combination (p< 0.001)
treatments significantly increased mean values of the learning
index during 5-day trials.
What-Where-Which (WWWhich) Task
There were no significant differences in locomotor activity and
total observation time among groups (for both, p > 0.05) (data
not shown). Artificial aging significantly impaired the DI in
comparison to the control group (p< 0.001), while no significant
difference was observed between the AA and AA+GBI groups
(p > 0.05). The CoQ10, PBM, and combination groups notably
increased the DI value as a recognition performance (p < 0.05,
p< 0.01, and p< 0.001, respectively) (Figure 4).
Biochemical Assessments
Mitochondrial ROS
The cerebral mitochondrial ROS levels rose markedly in the
AA group (p < 0.001), and rose even further in the AA+GBI
group (p < 0.01). Both PBM and CoQ10 treatments, alone and
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FIGURE 3 | (A) Latency times and (B) number of errors in different groups. Differences among groups were analyzed for each day. (C) Learning index in different
groups. (D) Corresponding sample tracks display the exploratory patterns during the last day of test. Values represent the mean ± SEM, (n = 15). ∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001 compared with the NS (control). #p < 0.05, ##p < 0.01, and ###p < 0.001 compared with the AA + GBI. AA, artificially aged; CoQ10,
Coenzyme Q10; GBI, global brain ischemia; NS, normal saline; PBM, photobiomodulation; Veh, Vehicle.
in combination, significantly returned the ROS values to the AA
group level (for all, p< 0.001), as shown in Figure 5A.
ATP
The AA group mice had significantly reduced ATP levels
(p < 0.001), with further significant reduction in the AA+GBI
group (p < 0.05), and the CoQ10 (p < 0.05), PBM (p < 0.05),
and combination (p< 0.01), treatments significantly returned the
ATP levels to the AA group level (Figure 5B).
Active Mitochondria Levels
There was a lower active mitochondria level in the AA group
(p < 0.01), with no further significant decline in the AA+GBI
group (p > 0.05). The PBM, CoQ10 (for both, p < 0.05), and in
combination (p < 0.01) separately, markedly and equally raised
the active mitochondria level (Figure 5C).
Western Blotting
SIRT1
SIRT1 levels were decreased in the AA group (p < 0.001),
whereas no significant difference was observed between the AA
and AA+GBI groups (p > 0.05). The CoQ10 (p < 0.05), PBM
(p < 0.05), and combination (p < 0.001) treatments partially
restored the SIRT1 levels (Figures 6A,D).
PGC1-α
Artificial aging significantly reduced the PGC-1α levels
(p < 0.001). Also, the AA+GBI group exhibited significantly
lower PGC-1α expression compared to the AA group (p < 0.01).
Both CoQ10 and PBM groups had significantly raised PGC1-α
levels (p < 0.001). In addition, the levels of PGC1-α were
markedly upregulated in the combination group (p < 0.001;
Figures 6B,D).
NRF1
Artificial aging significantly lowered NRF1 expression (p< 0.001)
that further declined in the AA+GBI group (p < 0.05). The
reductions were reversed by the CoQ10, PBM, and combination
treatments (p < 0.05, p < 0.001, and p < 0.001, respectively), as
shown in Figures 6C,D.
Cytosolic TFAM
Cytosolic TFAM was decreased in the AA group (p < 0.01),
whereas no significant difference was observed between the AA
and AA+GBI groups (p > 0.05). Although CoQ10 treatment
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FIGURE 4 | Displacement index (DI) in different groups. Each bar represents
the mean ± SEM, (n = 15). ∗∗∗p < 0.001 compared with the NS (control).
#p < 0.05, ##p < 0.01, and ###p < 0.001 compared with the AA + GBI. AA,
artificially aged; CoQ10, Coenzyme Q10; GBI, global brain ischemia; NS,
normal saline; PBM, photobiomodulation; Veh, Vehicle.
partially increased cytosolic TFAM levels (p< 0.01), this increase
was much more pronounced in both PBM and combination
treatment groups (for both, p< 0.001) (Figures 7A,C).
Mitochondrial TFAM
As shown in Figures 7B,C, mitochondrial TFAM was decreased
in the AA group (p < 0.05), whereas no significant difference
was observed between the AA and AA+GBI groups (p > 0.05).
However, both PBM and CoQ10 treatments, alone or in
combination, remarkably increased mitochondrial TFAM levels
(for all, p< 0.001).
iNOS
The artificial aging caused a significant increase in iNOS levels
(p < 0.001) that was further pronounced in the AA+GBI group
compared to the AA group (p< 0.05). Both the PBM and CoQ10
treatments, alone and in combination, significantly reversed the
effect on the iNOS levels (for all, p< 0.001) (Figures 8A,D).
IL-1β
As shown in Figures 8B,D, the AA group did not show a
significant increase in IL-1β levels (p > 0.05). However, the
AA+GBI group displayed significantly elevated IL-1β levels
compared to the AA group (p < 0.05). On the other hand, the
CoQ10 (p< 0.001), PBM (p< 0.001), and combination (p< 0.01)
treatments showed significantly reduced IL-1β expression levels.
TNF-α
As shown in Figures 8C,D, a remarkable increase was observed
in cerebral TNF-α levels in the AA group (p < 0.001).
Also, a strong increase in TNF-α levels was observed in
the AA+GBI group compared to the AA group (p < 0.05).
However, both PBM and CoQ10 treatments, alone or in
combination, significantly decreased TNF-α expression levels
(for all, p< 0.001).
DISCUSSION
Here, we demonstrated significant and substantial improvements
in neurobehavioral and molecular variables, including cerebral
bioenergetics and mitochondrial biogenesis, as well as the
neuroinflammatory response to artificial aging, in mice subjected
to a model of transient global ischemia, by the PBM or CoQ10
treatments, or both.
Impaired mitochondrial function and inflammatory responses
are considered crucial steps in the mechanisms involved in
the model of brain aging induced by D-galactose (Shan et al.,
2009; Kumar et al., 2010). In previous studies, aged animals
were shown to be more sensitive to cerebral injury induced by
an ischemic event (Canese et al., 1998; Xu et al., 2008), and
transient BCCAO is known to induce an ischemia-reperfusion
injury associated with oxidative damage to cortical neurons
(Yabuki and Fukunaga, 2013).
Mitochondria are the principal organelles responsible for
ATP generation and neuronal energy homeostasis (Onyango
et al., 2010). Injured cerebrovascular endothelium in contrast
is considered to be both source and target for ROS (Strasser
et al., 1997). Age-related over-production of ROS results
in endothelial apoptosis through oxidation of mitochondrial
proteins and damage to and mutations in mitochondrial DNA
(Dai and Rabinovitch, 2009). Likewise, a large body of evidence
demonstrates that increased mitochondrial ROS generation
follows chronic administration of D-galactose (Pratchayasakul
et al., 2017), simulating the ROS generated in aging brain.
Furthermore, transient reductions of CBF can deprive the
brain of O2 and glucose, further exacerbating mitochondrial
dysfunction (Sakoh et al., 2000).
Cerebral ischemia is prevalent in the aged population (Chen
et al., 2010). In addition, susceptibility to oxidative stress caused
by ischemic injury typically is higher in the aging brain compared
to the young healthy brain (Lucas and Szweda, 1998). Therefore,
oxidative damage induced by ischemic brain insults in the
aged population plays a cardinal role in the mitochondrial
dysfunction and subsequent cognitive decline in these subjects
(Fukui et al., 2002).
Based on the preliminary study using 810 nm laser light in
BALB/c mice (Salehpour et al., 2017), the fluence that reaches
the cortical surface is only 8 J/cm2, when 33.3 J/cm2 of laser
fluence is delivered to the scalp. In terms of light penetration
through the brain tissues of BALB/c mice, it has been reported
that approximately 3% of 810 nm laser photons reach a depth in
the brain of 5 mm, the distance from skull surface to substantia
nigra compacta (SNc) region (Reinhart et al., 2017). Therefore,
it could be presumed that in this study 0.25 J/cm2 of NIR light
reaches the brainstem, which is in the biostimulatory range for
PBM therapy (Sharma et al., 2011; Moro et al., 2014).
A main mechanism of the beneficial effect of NIR PBM
therapy relies on the improvement of mitochondrial function by
direct stimulation of the ETC (Salehpour et al., 2018d). In this
context, Lapchak and de Taboada (Lapchak and De Taboada,
2010) reported an increase in ATP content following 808 nm laser
therapy and proposed this mechanism as a possible explanation
for the reduction of ischemic tissue and the behavioral
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FIGURE 5 | (A) DCFDA intensity as mitochondrial ROS levels, (B) ATP content, and (C) MitoTracker Green (MTG) intensity as mitochondrial activity in brain tissue of
different groups. Each bar represents the mean ± SEM, (n = 8). ∗∗p < 0.01 and ∗∗∗p < 0.001 compared with the NS (control). $p < 0.05 and $$p < 0.01 compared
with the AA.#p < 0.05, ##p < 0.01, and ###p < 0.001 compared with PBM- AA + GBI. AA, artificially aged; CoQ10, Coenzyme Q10; GBI, global brain ischemia; NS,
normal saline; PBM, photobiomodulation; Veh, Vehicle.
improvements following experimentally induced stroke. Previous
experiments with specific cognitive impairment models have
shown that NIR PBM therapy can improve mitochondrial
functions by increasing ATP (Dong et al., 2015; Salehpour et al.,
2017) and mitochondrial membrane potential (MMP) (Salehpour
et al., 2017), and decreasing the over-production of ROS (Dong
et al., 2015; Salehpour et al., 2017, 2018c).
In the current study, NIR PBM therapy significantly
affected mitochondrial dysfunction induced by global ischemia
and D-galactose administration, as shown by increased ATP
synthesis and suppressed ROS production. To enhance the
therapeutic efficiency of PBM, we combined PBM with CoQ10,
a critical cofactor in the mitochondrial ETC known to improve
mitochondrial function. Four weeks of CoQ10 supplementation
exerted neuroprotection by decreasing the infarct volume
of an ischemic hemisphere in aged mice (Li et al., 2007).
Oral administration of CoQ10 for 30 days improved brain
bioenergetics and reduced the effects of transient cerebral
ischemia on mitochondrial function as indicated by increased
O2 consumption and ATP production (Horecky et al., 2011).
It is known that CoQ10 acts as a potent free radical scavenger
against cerebral ischemia-induced oxidative damage (Ostrowski,
2000). Thus, our results, along with others, confirm that CoQ10
supplementation rescues mitochondrial function and prevents
brain damage produced by a model of cerebral ischemia applied
to a model of aging in mice.
Altogether, data from the CoQ10 and PBM combination
regimen demonstrated slightly better results than those of
each separate treatment in terms of ATP and ROS levels.
In this regard, Dong et al. (Dong et al., 2015) have shown
that NIR (810 nm) PBM therapy in combination with
lactate or pyruvate synergistically increased hippocampal
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FIGURE 6 | (A) SIRT1, (B) PGC1-α, and (C) NRF1 levels in brain tissue of different groups. Each bar represents the mean ± SEM, (n = 6). ∗∗∗p < 0.001 compared
with the NS (control). $p < 0.05 and $$p < 0.01 compared with the AA. #p < 0.05 and ###p < 0.001 compared with AA + GBI. (D) Representative images of SIRT1,
PGC1-α and NRF1 protein levels detected by western blot. The GAPDH was used as an internal control. AA, artificially aged; CoQ10, Coenzyme Q10; GBI, global
brain ischemia; NRF1, nuclear respiratory factor 1; NS, normal saline; PBM, photobiomodulation; PGC1-α, peroxisome proliferator-activated receptor gamma
coactivator-1 alpha; SIRT1, silent mating-type information regulation 2 homolog 1; Veh, Vehicle.
ATP levels in a mouse model of TBI. However, results
from ROS levels did not show any significant differences
among combination and separate treatment groups
(Dong et al., 2015).
Although an exact understanding of the cellular mechanisms
underlying the suppression of cerebral overproduction of ROS
after PBM therapy is still missing, the upregulation of total
antioxidant capacity and some individual antioxidant enzymes
[such as superoxide dismutase (SOD) and glutathione peroxidase
(GPx)] may contribute to the beneficial effects (Lu et al., 2017;
Salehpour et al., 2018c). Besides antioxidants, SIRT1 is linked
to the oxidative stress response in cerebral ischemia (Raval
et al., 2008). Cellular defenses attenuate mitochondrial oxidative
damage, via activation of SIRT1 in cerebral ischemic injury
(Yang et al., 2015). In addition, SIRT1 directly affects PGC1-
α activity via phosphorylation and deacetylation (Cantó and
Auwerx, 2009). PGC1-α is a transcriptional coactivator that
upregulates the aforementioned antioxidant enzymes, SOD and
GPx (St-Pierre et al., 2003). Studies have shown a key role of
PGC1-α-mediated ROS metabolism in cerebral ischemia (Chen
et al., 2011). In this regard, a rise in PGC1-α expression level
has been proposed as a protective mechanism against ROS-
mediated neuronal death (St-Pierre et al., 2006). The antioxidant
effect of alpha-lipoic acid through the up-regulation of SIRT1-
dependent PGC1-α expression has also been reported in a
rat cerebral ischemia model (Fu et al., 2014). In our study,
PBM and/or CoQ10 significantly increased SIRT1 and PGC1-
α expression, and it seems that activation of SIRT1/PGC1-α
pathway could be another possible explanation for observed
reduction in ROS (Figure 9).
Total mitochondrial contents and the integrity of
mitochondrial DNA both are adversely affected by cerebral
ischemia because of the increase of oxidative stress (Chen et al.,
2011). Mitochondrial biogenesis alters the size and number of
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FIGURE 7 | (A) Cytosolic and (B) mitochondrial TFAM levels in brain tissue of different groups. Each bar represents the mean ± SEM, (n = 6). ∗p < 0.05 and
∗∗p < 0.01 compared with the NS (control). ##p < 0.01 and ###p < 0.001 compared with AA + GBI. (C) Representative images of cytosolic and mitochondrial TFAM
protein levels detected by western blot. The GAPDH and Cyt. c were used as cytosolic and mitochondrial internal controls, respectively. AA, artificially aged; CoQ10,
Coenzyme Q10; Cyt. c, cytochrome c; GBI, global brain ischemia; NS, normal saline; PBM, photobiomodulation; TFAM, mitochondrial transcription factor; Veh,
Vehicle.
individual mitochondrial units. Another essential function of
PGC1-α, as a master activator of mitochondrial biogenesis, is
regulation of mitochondrial content via transcription factors
such as NRF1 and NRF2, which in turn upregulate mitochondrial
gene expression, and TFAM can affect nuclear DNA (Hock and
Kralli, 2009). For instance, down-regulation of PGC1-α in
aluminum-treated rats along with a decrease of NRF1 and TFAM
(which act downstream from PGC1-α) resulted in decrease of
mitochondrial DNA copy number and mitochondrial abundance
in the hippocampus and corpus striatum regions of the brain
(Sharma et al., 2013). Moreover, SIRT1 could directly interact
with PGC-1α and increase its activity and expression, leading
to upregulation of mitochondrial gene expression (Nemoto
et al., 2005). Therefore, activation of mitochondrial biogenesis,
and thus the level of mitochondrial activity in neurons, has
substantial therapeutic potential since it may improve cerebral
bioenergetics in both ischemic brain insults and in general aging.
Although activation of mitochondrial biogenetic regulators
after PBM therapy has been reported in muscle (Nguyen et al.,
2014) and mesenchymal stem cells (Yin et al., 2017), there is no
reported evaluation of stimulatory effects of NIR PBM therapy
on neuronal mitochondrial biogenesis in the cerebral ischemic
aging model. It has been demonstrated that 4 days of NIR laser
irradiation (with dual wavelengths of 808+980 nm) can induce
mitochondrial biogenesis by elevation of SIRT1 and PGC-1α
in C2C12 muscle cells (Nguyen et al., 2014). Likewise, 660 nm
light has been shown to increase the expression of mitochondrial
biogenesis-associated genes including PGC-1α, NRF1, and
TFAM in mesenchymal stem cells at 24 h post-irradiation (Yin
et al., 2017). Increased transcription of NRF1 and TFAM through
the upregulation of SIRT1 and PGC-1α expressions has also been
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FIGURE 8 | (A) The iNOS, (B) IL-1β, and (C) TNF-α levels in brain tissue of different groups. Each bar represents the mean ± SEM, (n = 6). ∗∗∗p < 0.001 compared
with the NS (control). $p < 0.05 and $$$p < 0.001 compared with the AA.##p < 0.01 and ###p < 0.001 compared with AA + GBI. (D) Representative images of
iNOS, IL-1β, and TNF-α protein levels detected by western blot. The GAPDH was used as an internal control. AA, artificially aged; CoQ10, Coenzyme Q10; GBI,
global brain ischemia; IL-1β, interleukin-1β; iNOS, inducible NO synthase; NS, normal saline; PBM, photobiomodulation; TFAM, mitochondrial transcription factor;
TNF-α, tumor necrosis factor-α; Veh, Vehicle.
proposed for aging rat skeletal muscle following 810 nm PBM
therapy (Shaafi et al., 2014).
The present data showed that both PBM and/or CoQ10
could remarkably activate expression of genes, which are
involved in mitochondrial biogenesis. Based on the findings
from this preclinical research, we suggest that stimulation of
the SIRT1/PGC1-α/NRF1/TFAM signaling pathway by NIR PBM
and CoQ10 could regulate neuronal mitochondrial biogenesis,
thereby providing neuroprotection against delayed cell death
after cerebral ischemia, especially in aged brains (Figure 9). Taken
together, mitochondrial function is linked to mitochondrial
content that potentially can be improved by PBM therapy.
Increased mitochondrial activity in the brain following 810 nm
laser irradiation has been reported by this laboratory in animal
models of cognitive impairment (Salehpour et al., 2017, 2018c),
in line with the present results. Likewise, 2 weeks of CoQ10
treatment notably augmented the mitochondrial activity. Hence,
the findings provide evidence that stimulation of neuronal
mitochondrial biogenesis may be one of the key mechanisms
for NIR PBM and CoQ10 to increase mitochondrial content
and/or function, thus, attenuating cognitive impairment in
a model of global cerebral ischemia superimposed on a
model of aging.
It is believed that microglial cells activated in response to
brain ischemic insults exacerbate cerebral injury by releasing
pro-inflammatory TNF-α and IL-1β (Lakhan et al., 2009). The
accelerated proliferation of glial and endothelial cells after an
ischemic insult results in rapid infarct development in senescent
animals that display age-dependent ischemic outcomes (Popa-
Wagner et al., 2007). Decreased levels of TNF-α (De Taboada
et al., 2011; Lu et al., 2017; Yang et al., 2018) and IL-1β
(Moreira et al., 2009; De Taboada et al., 2011; Zhang et al.,
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FIGURE 9 | Schematic illustration of mechanisms involved in therapeutic effects of PBM and CoQ10.
2014; Lee et al., 2017; Lu et al., 2017) have been reported in
specific animal brain injury models following transcranial PBM
therapy. Pre-treatment with NIR PBM also resulted in significant
reduction of cerebral TNF-α and IL-1β levels in ischemic mice
(Lee et al., 2016). In accordance with the previous reports, our
results showed increased inflammatory responses in a model of
concurrent global ischemia superimposed on a model of aging in
mice, while both PBM and/or CoQ10 partially, but significantly,
attenuated the expression levels of TNF-α and IL-1β. Besides
the proinflammatory cytokines, increased activity of iNOS in
glia and infiltrating neutrophils leads to excessive amounts of
free radicals following ischemic injury (Lakhan et al., 2009). The
NO produced by iNOS within microglia and cerebrovascular
endothelium is also involved in the deleterious inflammatory
response occurring after ischemia (Zoppo et al., 2000). In vitro
(Yang et al., 2010) and in vivo (Leung et al., 2002; Lee et al.,
2016) studies support the idea that the anti-neuroinflammatory
effects of transcranial PBM therapy may at least partly be due
to its ability to modulate iNOS activity. In addition, CoQ10
treatment has been reported to attenuate hippocampal TNF-
α levels in a pentylenetetrazole-induced cognitive dysfunction
model (Bhardwaj and Kumar, 2016), and this finding is in
good agreement with our data (Figure 9). Moreover, a study by
Tsai et al. (Tsai et al., 2012) showed that CoQ10 could protect
human endothelial cells from oxidative stress via decreasing
iNOS expression.
To test whether PBM and/or CoQ10 protected against global
ischemia-induced cognitive impairment performance in our
aged-mouse model, we evaluated the animals in a test of spatial
and episodic-like memories. Since the hippocampus plays a
key role in the consolidation of memories related to spatial
navigation, we subjected mice to the Barnes and Lashley III
mazes as hippocampus-dependent spatial learning and memory
tasks. The data showed that administration of D-galactose
and global ischemia induction together significantly impaired
spatial learning and memory, which is in line with previous
reports (Xu et al., 2000; Sadigh-Eteghad et al., 2017; Salehpour
et al., 2017). On the other hand, 2 weeks of PBM and/or
CoQ10 treatments significantly reversed this deficiency. The
procognitive benefits of NIR PBM therapy to spatial memory
have been shown with the Morris water maze (De Taboada
et al., 2011; Dong et al., 2015) and Barnes maze (Lu et al., 2017;
Salehpour et al., 2017, 2018c) in different animal models. It is
well established that the hippocampal bioenergetic capacity and
neuronal survival are linked to spatial memory and learning
(Sadowski et al., 2004).
In this study, we tentatively conclude that augmentation
of brain bioenergetic capacity and the accompanying
neuroprotective effects were reflected in improved learning
and memory performances in both NIR PBM and CoQ10
treated mice. We observed that NIR PBM therapy notably
improved the episodic memory of the D-galactose-treated mice
in the BCCAO model of cerebral ischemia. This result is in
line with previous reports of Lu et al. (Lu et al., 2017) and
Salehpour et al. (Salehpour et al., 2017, 2018c) who demonstrated
enhanced recognition memory after transcranial 810-nm
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laser therapy. Moreover, CoQ10 supplementation significantly
rescued recognition memory as indicated by higher DI which is
in line with other work (Llewellyn et al., 2015).
Since both chronic injection of D-galactose and subjection
of animals to global cerebral ischemia result in systemic
damage to the brain and nervous system, we examined
the whole brain for possible neurochemical alterations.
Furthermore, to test whether treatments protected against global
ischemia-induced cognitive decline in the aged animal model,
we subjected mice to the Barnes maze and Lashley III maze (as
hippocampus-dependent spatial learning and memory tasks) and
the WWWhich task (as a prefrontal cortex-dependent episodic
memory task).
We note that the Red/NIR light propagation in the brain raises
an important issue for purposes of treatment. Lambert-Beer’s
law explains attenuation of photon propagation in biological
media. Most recently, we showed that approximately 1% of the
light incident onto the scalp surface reaches a 1-mm depth
from the cortical surface, penetrating the dorsal hippocampus
of the mouse, when a laser beam is focused on the bregma,
(Salehpour et al., 2018a). Therefore, in the current study, we
assumed that the cortical neurons and upper layers of the
hippocampus received more photons than deeper structures
(i.e., thalamus and hypothalamus). Given this, we also assumed
that the neurochemical effects would be stronger if only the
hippocampus had been sampled. However, further studies are
needed to gain more insight into specific brain regions (i.e.,
hippocampus, prefrontal cortex, and amygdala) that are affected
by PBM therapy of cognitive impairment.
Although the administration of CoQ10 affects brain
function systemically and globally, the upper cortical layers
are mainly affected by transcranial PBM therapy due to the
aforementioned biophysical properties. Hence, the restricted
light penetration is a potential interpretative limitation
of the studies (brain and non-brain tissues) of possible
synergistic effects of the combination of PBM therapy and
pharmacotherapy strategies.
CONCLUSION
We conclude that NIR PBM combined with CoQ10 had multiple
mechanisms of action, targeting mitochondrial bioenergetics
and biogenesis as well as anti-neuroinflammation in this model
of ischemic brain damage in AA animals. The present study
suggests that the PBM and CoQ10 treatments, alone or in
combination, have procognitive effect in ischemic damage to
aged brains of mice. It is noteworthy that the translation of
the concepts of the current study in terms of models and
conditions into humans is challenging. However, considering
the number of elderly patients that sustain significant brain
damage following a heart attack or ischemic stroke each
year, it makes sense to test this relatively inexpensive and
completely non-hazardous intervention (or combination of
interventions) in humans. Further complementary preclinical
and clinical studies are warranted for clarification of other
potential applications in this area.
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